Launch of AliveDx Scientific Insights Center

We are excited to announce the launch of the AliveDx Scientific Insights Center on the AliveDx website.

The Scientific Insights Center provides laboratorians and the medical community access to key published scientific communications. It offers valuable insights to help navigate the complexities of autoimmune and allergy disease diagnostics. Our goal is to empower them with knowledge, enabling them to provide accurate answers to patients and ultimately improve their lives.

The publications explore key topics in autoimmune connective tissue diseases, celiac disease, and allergies, and feature insights from AliveDx experts and other external partners.

We hope these resources will provide valuable scientific insights to healthcare professionals.

Trending Topics

Our passion for the work we do is matched only by our commitment to consistently provide the best customer experience possible.

February 18, 2025

Alba Bioscience completes UK NHS Evergreen Sustainable Supplier Assessment and achieves Level 2

Alba Bioscience is pleased to have completed the UK National Health Service (NHS) Evergreen Sustainable Supplier Assessment. The Assessment is a self-assessment and reporting tool and resulted in Alba Bioscience receiving a Level 2: Comprehensive net zero targets and reporting
February 7, 2025

AliveDx Suisse S.A. and Sedeer Medical Services and Trading Co. LLC Sign Distribution Agreement in Qatar

AliveDx Suisse S.A. and Sedeer Medical Services and Trading Co. LLC have signed a distribution agreement, which will enable Sedeer to distribute the MosaiQ® and LumiQ™ solutions in Qatar. The distribution agreement takes effect immediately. AliveDx is committed to expanding
January 7, 2025

MosaiQ AiPlex® Celiac Disease (CD) system now available in the EU market and other geographies that recognize the CE mark

We are excited to announce that our IVDR-CE marked MosaiQ AiPlex® Celiac Disease (CD) system is now available in the EU market and other geographies that recognize the CE mark (pending local registration in some countries). Celiac Disease is a
December 10, 2024

AliveDx Announces Multiple Evaluation Sites of its MosaiQ® Solution

AliveDx is dedicated to expanding its reach and presence across diverse regions, with the goal of delivering both clinical and economical value to clinicians by reducing the time to diagnosis for patients suffering from autoimmune and allergy diseases. We are
December 5, 2024

Join us at the upcoming International Friday Meeting

We are delighted to speak at the upcoming International Friday Meeting on Friday, 6 December 2024 at 6:30AM CET. The International Friday Meeting is a monthly meeting, held on the first Friday of the month, hosted by Pr. Yehuda Shoenfeld.
November 11, 2024

AliveDx Suisse S.A. and Medikonia Limited Sign Distribution Agreement in Hong Kong and Macau

AliveDx Suisse S.A. and Medikonia Limited have signed a distribution agreement, which will enable Medikonia to distribute the MosaiQ® solution in Hong Kong and Macau. The distribution agreement takes effect immediately. AliveDx is committed to broadening its reach and presence